Associations among regorafenib concentrations, severe adverse reactions, and ABCG2 and OATP1B1 polymorphisms
Akimitsu Maeda,
Kei Irie,
Hitoshi Ando,
Ayako Hasegawa,
Hiroya Taniguchi,
Shigenori Kadowaki,
Kei Muro,
Masahiro Tajika,
Masahiro Aoki,
Kazuhide Inaguma,
Cancer Chemotherapy and Pharmacology · 2018 · 15 citations · 21 references